

**Talking Points on 340B Rebate Pilot
December 12, 2025**

- Over the last few weeks, Community Health Centers in my district have informed me that the upcoming 340B rebate pilot program will severely restrict their patients' access to affordable medications in rural and remote areas.
- Health centers use 340B discounts and a sliding fee scale to lower prices for medication and essential health services for their communities.
- The rebate program will cause an overnight 300% to 200,000% increase in prices for medication that treats diabetes and arthritis and prevents life-threatening strokes.
- Higher upfront costs will force patients off medicine that keeps them healthy, decrease pharmacy access options, and destabilize health centers' operations.
- It's time for us to take up legislation to exempt health centers from the 340B rebate pilot and advance common-sense transparency and accountability measures.

Expected price jumps for commonly prescribed medication due to the rebate model:

Drug	Upfront Price Increase	What the Medication Does
Eliquis	6,234%	These are blood thinners that prevent blood clots and strokes. These are vital life-saving therapies that keep patients out of the ER and prevent hospital admissions.
Xarelto	135,933%	
Farxiga	725%	These medicines help manage blood sugar levels in adults with type 2 diabetes. They are helpful not only for type 2 diabetes, but also for chronic kidney disease, heart failure, and prevention of cardiovascular disease.
Jardiance	209,682%	
Januvia	1,044%	A mainstay of type 2 diabetes treatment in primary care.
Novolog	315%	Fast acting insulin to control high blood sugar in patients with type 1 and type 2 diabetes.

Constituent story on how 340B rebate pilot affects health center patients-

- In my district, [insert story here]